The Pharmacy and Poisons Board has cautioned Kenyans against the unapproved use of the common antihistamine cetirizine, following misleading social media claims that the tablets can be used for vaginal tightening or to induce vaginal dryness.
In an advisory signed by Chief Executive Officer Dr Ahmed Mohamed, the board clarified that cetirizine is an oral medication meant to manage allergy symptoms such as allergic rhinitis and urticaria. It is neither approved for vaginal use nor supported by any scientific evidence for such purposes.
The board and medical experts warn that inserting oral tablets into the body in unapproved ways poses significant health risks. Possible complications include local irritation such as burning, stinging, intense pain, soreness and inflammation of the tissue.
Introducing unauthorised substances can also alter the delicate vaginal microbiome, increasing susceptibility to infections.
Exceeding the recommended dosage can trigger adverse systemic reactions, including drowsiness, dizziness, fatigue, confusion, restlessness, tremors, a rapid heart rate and urinary difficulties.
The board has urged the public to rely on verified medical advice and avoid participating in or sharing unverified health trends circulating online. People with vaginal health concerns or questions on sexual wellness are advised to consult qualified healthcare professionals rather than rely on social media.
Consumers who experience adverse effects or wish to report safety concerns about any medical product can contact the board through:
• its online portal at pv.pharmacyboardkenya.org/users/mpublic
• the mPVERS mobile application for Android and iOS
• email at pv@ppb.go.ke or pms@ppb.go.ke
• telephone on 0795743049
The board reiterated its commitment to safeguarding public health and ensuring that only safe, quality and effective health products are used in the country.
Reader Discussion (0)
Sign in to comment